FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells.
about
A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasisA transcriptional repressor co-regulatory network governing androgen response in prostate cancersWnt signalling in smooth muscle cells and its role in cardiovascular disordersFrizzled homolog proteins, microRNAs and Wnt signaling in cancerParametric analysis of colony morphology of non-labelled live human pluripotent stem cells for cell quality control.Initial steps of metastasis: cell invasion and endothelial transmigrationWnt/β-catenin signalling in prostate cancerTMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer modelHigh-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancerERG transcriptional networks in primary acute leukemia cells implicate a role for ERG in deregulated kinase signalingERG is a critical regulator of Wnt/LEF1 signaling in prostate cancerA cell spot microarray method for production of high density siRNA transfection microarrays.TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling.Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle?TMPRSS2:ERG gene fusion variants induce TGF-β signaling and epithelial to mesenchymal transition in human prostate cancer cellsGenetic variants of the Wnt signaling pathway as predictors of recurrence and survival in early-stage non-small cell lung cancer patientsAndrogen receptor as a driver of therapeutic resistance in advanced prostate cancer.Molecular pathways and targets in prostate cancerEpsin is required for Dishevelled stability and Wnt signalling activation in colon cancer developmentFISH Oracle 2: a web server for integrative visualization of genomic data in cancer research.The role of epithelial plasticity in prostate cancer dissemination and treatment resistanceERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer.The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis.The endothelial transcription factor ERG promotes vascular stability and growth through Wnt/β-catenin signaling.Inhibition of androgen receptor and β-catenin activity in prostate cancerProfiling gene promoter occupancy of Sox2 in two phenotypically distinct breast cancer cell subsets using chromatin immunoprecipitation and genome-wide promoter microarraysERG oncoprotein inhibits ANXA2 expression and function in prostate cancerInactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells.miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT.WMAXC: a weighted maximum clique method for identifying condition-specific sub-network.Mesd is a general inhibitor of different Wnt ligands in Wnt/LRP signaling and inhibits PC-3 tumor growth in vivo.Androgen receptor-interacting protein HSPBAP1 facilitates growth of prostate cancer cells in androgen-deficient conditions.Expression of ERG protein in prostate cancer: variability and biological correlates.Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate TumorsLoss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate CancersOncogenic activation of ERG: A predominant mechanism in prostate cancer.The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletionCRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activitiesHOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomyOverexpression of ETV4 is oncogenic in prostate cells through promotion of both cell proliferation and epithelial to mesenchymal transition
P2860
Q24307454-F763D55A-B480-4C0C-9EAA-AF90402888B8Q24317244-780D38EE-D480-4032-A6E7-3D0381DD2C39Q26849336-0372362D-7CF5-4246-99A0-1544DAFA7131Q27010132-6A7C0F56-A0F5-4B8E-B34A-9E65E2ADC3DFQ27345030-7D58301E-7364-4514-958D-67AB2A097CEEQ28238397-7D982193-635D-4AFB-9DA3-306EEDD3E3B5Q28269116-06F8D7C2-9412-4EBD-AF66-A6DE315EABF0Q28478908-E91826D5-2871-4B2F-AF45-08C394828546Q28480861-98ED80FF-406A-4F48-AA23-6178215DFF6CQ28484833-7B49AB12-F783-408F-8E99-BEF25BB31101Q28771736-788609BF-7C84-4EE0-B9C5-B763E0CA1580Q30499422-3247C8B9-0026-42BB-8616-79636CEF3E88Q31042968-A156A279-E429-47AE-B0DC-1F31AAE5A8C3Q33351622-6AADAC97-34C3-4C49-B561-9AE52407DD94Q33648775-FF60A525-7CA1-4BA3-8616-E3D4E94EC25CQ33705233-DB0D5E2F-F03E-46A9-97CD-5538CF88DBE6Q33775723-82074F63-85EF-44A1-A238-04CB64F05110Q34365632-81C4AE88-B751-4425-8C03-A27FC5F63CA2Q34471536-9A7A893E-6483-4357-9482-A79116E2BC77Q34504704-92108EEE-65A7-4F68-B270-3FA026A945A8Q34505037-E0F17A0E-FE7B-4FED-AD61-1A842D100CC0Q34652823-9BF2BDA3-C9C8-4DF8-8856-8227D35A1B7BQ34699785-860A4C52-53DF-4034-A423-2C2AEC2A64FFQ34939997-F7DC07E5-1606-4C33-BF19-2AB5C26D38B6Q34982553-471347C8-A548-423E-9719-9D59A2E898D6Q35000680-D27A1F9B-E94C-4BEA-B898-7438D43B2CA6Q35108911-B7435F1F-220F-4BC5-AC20-D89A26D5E813Q35199287-5CC6B23C-0F2B-4625-8CC5-0A0735BB01C5Q35207623-0CDEFD16-3137-4643-BCF7-39FA76184160Q35229964-A89C7053-2826-4106-BDC3-8C3C55D9C171Q35243349-1DFBBDDB-437A-4BA6-816A-3DF8B92FDA3AQ35380142-227C8E6C-8D0C-4CBE-8D82-05F161744FC0Q35608000-9B6C52E7-1F76-4809-9054-C149CC667AC3Q35631603-A91996F8-EBC8-494B-80CC-1159F5DF2910Q35648290-464CF103-31C3-42FB-9A4C-EB624529387CQ35685920-FE2F4C6C-6D94-4979-AB46-0CA5097692ADQ35706611-DAEEEBDE-D699-42BF-8B79-942F3C41FC66Q35828490-A9440DB1-889B-4947-AB33-2C629F549451Q35828702-D3F42A87-3221-4FA9-9B6F-5720C28D478BQ36143137-18D9B441-300C-4ABF-880E-569D3E2B61E1
P2860
FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
FZD4 as a mediator of ERG onco ...... n human prostate cancer cells.
@en
FZD4 as a mediator of ERG onco ...... n human prostate cancer cells.
@nl
type
label
FZD4 as a mediator of ERG onco ...... n human prostate cancer cells.
@en
FZD4 as a mediator of ERG onco ...... n human prostate cancer cells.
@nl
prefLabel
FZD4 as a mediator of ERG onco ...... n human prostate cancer cells.
@en
FZD4 as a mediator of ERG onco ...... n human prostate cancer cells.
@nl
P2093
P50
P1433
P1476
FZD4 as a mediator of ERG onco ...... in human prostate cancer cells
@en
P2093
Henri Sara
John Patrick Mpindi
Juha Rantala
Kalle Alanen
Kristiina Iljin
Santosh Gupta
Tuomas Mirtti
P304
P356
10.1158/0008-5472.CAN-10-0244
P407
P577
2010-08-16T00:00:00Z